This trial studies pembrolizumab as a treatment for B-cell non-Hodgkin lymphoproliferative diseases.
2 Primary · 8 Secondary · Reporting Duration: Up to 5 years
Experimental Treatment
9 Total Participants · 1 Treatment Group
Primary Treatment: Pembrolizumab · No Placebo Group · Phase 2
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: